Literature DB >> 3382413

Microsomal fatty acid desaturation and elongation in a human lung carcinoma grown in nude mice.

R J de Antueno1, G Niedfeld, M E De Tomás, O F Mercuri, L Montoro.   

Abstract

Since tumor cells show abnormal fatty acid composition, it is likely that their desaturase systems were affected to some extent. Although desaturase activities in experimental tumors have been evaluated, to our knowledge, fatty acid desaturases in human neoplasms and particularly in human tumors grown in nude mice have not been assessed yet. We have therefore, chosen a rapidly growing human lung mucoepidermoid carcinoma (HLMC) grown in nude mice to study microsomal fatty acid desaturation and chain elongation activities. Tumor microsomal proteins were incubated with unlabeled malonyl-CoA and one of the following fatty acids: [1-14C]palmitic (16:0), [1-14C]linoleic (18:2), alpha-[1-14C]linolenic (alpha-18:3), and unlabeled gamma-linolenic (gamma-18:3) plus [2-14C]malonyl-CoA. Data show that HLMC microsomes were capable to desaturate 16:0, alpha-18:3, and dihomogammalinolenic acids (20:3) by delta 9, delta 6 and delta 5 desaturase, respectively; however, delta 6 desaturase activity on [14C]18:2 was not detected. The microsomal elongation system was active in all fatty acid series tested except for 18:2. These findings show that the undetectable activity for 18:2 desaturation is not exclusively found in experimental tumors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3382413

Source DB:  PubMed          Journal:  Biochem Int        ISSN: 0158-5231


  2 in total

1.  The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue.

Authors:  D D Martin; M E Robbins; A A Spector; B C Wen; D H Hussey
Journal:  Lipids       Date:  1996-12       Impact factor: 1.880

2.  In vivo and in vitro biotransformation of the lithium salt of gamma-linolenic acid by three human carcinomas.

Authors:  R de Antueno; M Elliot; G Ells; P Quiroga; K Jenkins; D Horrobin
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.